CRISPR Therapeutics AG (CRSP)

Schlusskurs vom Vortag:

$53.73

Offen:

$54.21

24-Stunden-Volumen:

1.35M

Marktkapitalisierung:

$4.58B

Einnahmen:

$170.10M

Nettoeinkommen (Verlust:

$-153.61M

KGV:

-12.06

EPS:

-4.47

Netto-Cashflow:

$-272.35M

1W Leistung:

-2.07%

1M Leistung:

-24.04%

6M Leistung:

+37.84%

1J Leistung:

+10.81%

1-Tages-Spanne:

$52.81

$54.94

52-Wochen-Spanne:

$37.55

$91.10

CRISPR Therapeutics AG Stock (CRSP) Company Profile

Firmenname

CRISPR Therapeutics AG

Sektor

Healthcare (1191)

Branche

Biotechnology (688)

Telefon

41 41 561 3277

Adresse

Baarerstrasse 14, Zug

Mitarbeiter

127

Twitter

@crisprtx

Nächster Verdiensttermin

2024-02-21

Neueste SEC-Einreichungen

CRSP's Discussions on Twitter

CRISPR Therapeutics AG Stock (CRSP) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2023-12-11	Herabstufung	TD Cowen	Market Perform → Underperform
2023-10-17	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-09-27	Eingeleitet	Mizuho	Buy
2023-08-17	Hochstufung	Citigroup	Neutral → Buy
2023-05-30	Eingeleitet	William Blair	Outperform
2023-04-13	Eingeleitet	Cantor Fitzgerald	Overweight
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2023-03-17	Eingeleitet	Bryan Garnier	Buy
2023-03-07	Eingeleitet	Robert W. Baird	Neutral
2022-10-11	Eingeleitet	Morgan Stanley	Underweight
2022-08-09	Herabstufung	Barclays	Overweight → Equal Weight
2022-06-23	Herabstufung	Evercore ISI	Outperform → In-line
2022-06-17	Eingeleitet	BMO Capital Markets	Outperform
2022-04-28	Eingeleitet	Credit Suisse	Neutral
2021-12-07	Eingeleitet	Cowen	Market Perform
2021-10-19	Eingeleitet	SVB Leerink	Outperform
2021-06-14	Hochstufung	Citigroup	Sell → Neutral
2021-04-21	Hochstufung	Jefferies	Hold → Buy
2021-03-04	Eingeleitet	JMP Securities	Mkt Outperform
2020-12-10	Bestätigt	Chardan Capital Markets	Buy
2020-12-10	Herabstufung	Jefferies	Buy → Hold
2020-12-10	Bestätigt	Needham	Buy
2020-12-07	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-10-23	Eingeleitet	RBC Capital Mkts	Sector Perform
2020-10-05	Eingeleitet	BofA Securities	Buy
2020-07-28	Bestätigt	Needham	Buy
2020-07-14	Eingeleitet	SunTrust	Buy
2020-06-15	Bestätigt	Canaccord Genuity	Buy
2020-03-05	Eingeleitet	Stifel	Hold
2020-02-03	Herabstufung	Evercore ISI	Outperform → In-line
2019-11-19	Hochstufung	William Blair	Mkt Perform → Outperform
2019-11-12	Hochstufung	Oppenheimer	Perform → Outperform
2019-08-01	Eingeleitet	Jefferies	Buy
2019-07-26	Eingeleitet	Canaccord Genuity	Buy
2019-06-10	Eingeleitet	ROTH Capital	Buy
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2019-03-14	Eingeleitet	William Blair	Mkt Perform
2019-01-28	Herabstufung	Goldman	Buy → Neutral
2019-01-22	Herabstufung	Citigroup	Neutral → Sell

Alle ansehen

CRISPR Therapeutics AG Aktie (CRSP) Neueste Nachrichten

CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note

Zacks Investment Research

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

The Motley Fool

Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?

The Motley Fool

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

Zacks Investment Research

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

GlobeNewswire Inc.

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update

Seeking Alpha

Finanzdaten der CRISPR Therapeutics AG-Aktie (CRSP)

CRISPR Therapeutics AG (CRSP) Umsatz 2024

CRISPR Therapeutics AG (CRSP) Nettogewinn 2024

CRISPR Therapeutics AG (CRSP) Free Cashflow 2024

CRISPR Therapeutics AG (CRSP) Gewinn je Aktie 2024